SCHEMBL365853

SCHEMBL365853

COc1ccc(Cn2cc3c(n2)CCCCC(Br)C3=O)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AADAT Q8N5Z0 1/20 0.45
ALDH1A1 P00352 2/20 0.41
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GSK3A P49840 2/20 0.39
GSK3B P49841 2/20 0.39
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
CMA1 P23946 1/20 0.38
ELANE P08246 1/20 0.38
MAPK1 P28482 1/20 0.38
BCHE P06276 1/20 0.38
PDE5A O76074 3/20 0.37
PDE4A P27815 3/20 0.37
PDE4B Q07343 3/20 0.37
PDE4C Q08493 3/20 0.37
PDE4D Q08499 3/20 0.37
LMNA P02545 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6837143 0.98 AADAT (0.45) AADATALDH1A1POLBSMN1; SMN2GSK3A
SCHEMBL15182499 0.83 AADAT (0.47) AADATALDH1A1POLBSMN1; SMN2GSK3A
SCHEMBL6837301 0.82 ALDH1A1 (0.48) AADATALDH1A1POLBSMN1; SMN2GSK3A
SCHEMBL365659 0.82 ALDH1A1 (0.48) AADATALDH1A1POLBSMN1; SMN2GSK3A
SCHEMBL366319 0.81 AADAT (0.47) AADATGSK3AGSK3BCMA1MEN1
SCHEMBL7684049 0.81 AADAT (0.47) AADATSMN1; SMN2GSK3AGSK3BCMA1
SCHEMBL365849 0.81 AADAT (0.44) AADATALDH1A1GSK3AGSK3BCMA1
SCHEMBL365650 0.81 AADAT (0.46) AADATGSK3AGSK3BCMA1MEN1
SCHEMBL365862 0.79 AADAT (0.42) AADATSMN1; SMN2GSK3AGSK3BCMA1
SCHEMBL366654 0.79 AADAT (0.44) AADATALDH1A1POLBSMN1; SMN2GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 AADAT 837/4885ALDH1A1 3331/4885POLB 4521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.